GlassScriptPhysician profile
Stanley Daniel Miller
NPI 1902851710
$6,887.95
in general payments reported to CMS, 2019-2025
47 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $219 · 2021: $922 · 2022: $1,259 · 2023: $1,018 · 2024: $1,273 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,369.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,242.93 | 2019-2025 | Biktarvy, Veklury |
| Merck Sharp & Dohme LLC | $647.98 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Viiv Healthcare Company | $573.58 | 2019-2025 | Dovato, Rukobia |
| Novo Nordisk INC | $457.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $408.74 | 2019-2025 | |
| Amgen INC. | $370.55 | 2019-2025 | Repatha, Otezla, Otezla |
| Shionogi INC | $315.62 | 2021-2025 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.57 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $213.72 | 2020-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $203.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Melinta Therapeutics, LLC | $196.47 | 2022-2024 | Kimyrsa, Vabomere, Rezzayo |
| Pfizer INC. | $191.72 | 2023-2025 | |
| Lilly USA, LLC | $191.33 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $161.60 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $160.02 | 2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.